MCID: BRR014
MIFTS: 63

Barrett Esophagus

Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Barrett Esophagus

MalaCards integrated aliases for Barrett Esophagus:

Name: Barrett Esophagus 57 12 53 75 29 55 44 73
Barrett's Esophagus 12 53 37 15 40
Barrett Esophagus/esophageal Adenocarcinoma 57 13 6
Barrett's Ulcer of Esophagus 12 73
Ulcerative Esophagitis 12 73
Barrett Metaplasia 57 75
Barrett Syndrome 76 53
Chronic Peptic Ulcer and Esophagitis Syndrome 53
Barrett's Esophagus with Esophagitis 12
Adenocarcinoma of the Esophagus 59
Adenocarcinoma of Esophagus 73
Esophageal Adenocarcinoma 59
Peptic Ulcer of Esophagus 73
Esophagitis-Peptic Ulcer 53
Columnar-Like Esophagus 53
Barrett's Oesophagus 12
Barretts Syndrome 12
Barrett Ulcer 53
Cle 12
Be 75

Characteristics:

Orphanet epidemiological data:

59
adenocarcinoma of the esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: adult;

HPO:

32
barrett esophagus:
Inheritance somatic mutation


Classifications:



Summaries for Barrett Esophagus

NIH Rare Diseases : 53 Barrett esophagus is a condition in which the lining of the esophagus (the tube that carries food from the throat to the stomach) is replaced by tissue that is similar to the lining of the intestines. Although this change does not cause any specific signs or symptoms, it is typically diagnosed in people who have long-term gastroesophageal reflux disease (GERD). The exact underlying cause of Barrett esophagus is not known; however, it generally occurs sporadically in people with no family history of the condition. Treatment varies by the severity of the condition and generally includes medications and life style modifications to ease the symptoms of GERD. Endoscopic or surgical treatments may be recommended in people with severe cases.

MalaCards based summary : Barrett Esophagus, also known as barrett's esophagus, is related to esophageal disease and adenocarcinoma. An important gene associated with Barrett Esophagus is ASCC1 (Activating Signal Cointegrator 1 Complex Subunit 1), and among its related pathways/superpathways are Pathways in cancer and Cell cycle. The drugs Abstral and Actiq have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and endothelial, and related phenotypes are obesity and clinodactyly of the 5th toe

OMIM : 57 Barrett esophagus, or Barrett metaplasia, describes the phenotypic change of normal esophageal squamous epithelium to a columnar and intestinal-type epithelium. This metaplastic change is important because patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett metaplasia is gastroesophageal reflux (GER; 109350). The retrograde movement of acid and bile salts from the stomach into the esophagus in this disease causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes (summary by Wong et al., 2005). (614266)

UniProtKB/Swiss-Prot : 75 Barrett esophagus: A condition characterized by a metaplastic change in which normal esophageal squamous epithelium is replaced by a columnar and intestinal-type epithelium. Patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett esophagus is gastroesophageal reflux. The retrograde movement of acid and bile salts from the stomach into the esophagus causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes.

Wikipedia : 76 Barrett\'s esophagus refers to an (abnormal) change in the cells of the lower portion of the esophagus.... more...

Related Diseases for Barrett Esophagus

Diseases related to Barrett Esophagus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 222)
# Related Disease Score Top Affiliating Genes
1 esophageal disease 32.8 CDX2 GAST PTGS2 TP53
2 adenocarcinoma 31.8 ASCC1 CCND1 CDKN2A CTHRC1 PTGS2 TP53
3 gastroesophageal reflux 31.5 CDX2 GAST PTGS2 TP53
4 tubular adenocarcinoma 31.2 CDX2 KRT20 MUC2
5 esophageal cancer 30.9 CCND1 CDKN2A CDX2 GSTP1 PTGS2 TP53
6 bile reflux 30.8 CDX2 PTGS2
7 transitional cell carcinoma 30.7 CDKN2A KRT20 KRT7 PTGS2 TP53
8 gastric cancer 29.6 CCND1 CDKN2A CDX2 GAST GSTP1 MUC2
9 high-grade dysplasia in patients with barrett esophagus 12.1
10 prune belly syndrome 11.6
11 mungan syndrome 11.4
12 leukoencephalopathy with vanishing white matter 11.2
13 emphysema, congenital lobar 11.2
14 brain stem astrocytic neoplasm 11.2 CDKN2A TP53
15 ovary neuroendocrine neoplasm 11.1 CDX2 KRT7
16 anal gland adenocarcinoma 11.1 KRT7 MUC5AC
17 cap polyposis 11.1 MUC2 MUC5AC
18 visceral myopathy 11.1
19 breast papillomatosis 11.1 CCND1 CDKN2A
20 inverted transitional papilloma 11.1 CDKN2A KRT7
21 anus adenocarcinoma 11.1 CDX2 KRT7 MUC5AC
22 polyposis, skin pigmentation, alopecia, and fingernail changes 11.1 CDX2 MUC2 MUC5AC
23 protoplasmic astrocytoma 11.1 PTGS2 TP53
24 anal canal adenocarcinoma 11.1 CDX2 KRT7 MUC5AC
25 bile duct mucoepidermoid carcinoma 11.0 KRT7 MUC2 MUC5AC
26 mucinous adenofibroma 11.0 CDX2 KRT7
27 bladder carcinoma in situ 11.0 CDKN2A KRT7 TP53
28 malignant spiradenoma 11.0 KRT7 TP53
29 cystic basal cell carcinoma 11.0 KRT20 KRT7
30 proliferative verrucous leukoplakia 11.0 CDKN2A MCM2
31 chronic ethmoiditis 11.0 MUC2 MUC5AC MUC6
32 necrotizing sialometaplasia 11.0 CDKN2A KRT7 TP53
33 barrett's adenocarcinoma 11.0 CDKN2A PTGS2 TP53
34 anus cancer 11.0 CDKN2A CDX2 KRT7
35 basaloid squamous cell carcinoma 11.0 CDKN2A KRT7 TP53
36 bladder squamous cell carcinoma 11.0 CDKN2A PTGS2 TP53
37 vulva cancer 11.0 CDKN2A KRT7 TP53
38 bowenoid papulosis 11.0 CCND1 CDKN2A PTGS2
39 oral leukoplakia 11.0 CCND1 CDKN2A TP53
40 ethmoid sinusitis 11.0 MUC2 MUC5AC MUC6
41 lupus erythematosus tumidus 11.0
42 pancreatic intraductal papillary-mucinous neoplasm 11.0 MUC2 MUC6
43 papillary adenocarcinoma 11.0 KRT7 MUC2 TP53
44 pylorospasm 11.0 GAST MUC5AC
45 vaginal benign neoplasm 11.0 CDX2 KRT20 KRT7
46 appendix adenocarcinoma 11.0 CDX2 KRT20 KRT7
47 seminal vesicle adenocarcinoma 11.0 KRT20 KRT7
48 vaginal adenoma 11.0 CDX2 KRT20 KRT7
49 vaginal tubulovillous adenoma 11.0 CDX2 KRT20 KRT7
50 glandular cystitis 11.0 CDX2 KRT20 KRT7

Graphical network of the top 20 diseases related to Barrett Esophagus:



Diseases related to Barrett Esophagus

Symptoms & Phenotypes for Barrett Esophagus

Clinical features from OMIM:

614266

Human phenotypes related to Barrett Esophagus:

59 32 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 obesity 59 32 hallmark (90%) Very frequent (99-80%) HP:0001513
2 clinodactyly of the 5th toe 59 32 hallmark (90%) Very frequent (99-80%) HP:0001864
3 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
4 gastroesophageal reflux 59 32 hallmark (90%) Very frequent (99-80%) HP:0002020
5 lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002716
6 feeding difficulties in infancy 59 32 hallmark (90%) Very frequent (99-80%) HP:0008872
7 esophageal carcinoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0011459
8 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
9 barrett esophagus 59 32 hallmark (90%) Very frequent (99-80%) HP:0100580
10 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749

MGI Mouse Phenotypes related to Barrett Esophagus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.06 CCND1 CDKN2A CDX2 GAST MCM2 MUC2
2 homeostasis/metabolism MP:0005376 9.97 AMACR CCND1 CDKN2A CDX2 CTHRC1 GAST
3 endocrine/exocrine gland MP:0005379 9.96 GAST GDF7 MCM2 MUC2 PTGS2 RAB11A
4 immune system MP:0005387 9.7 RAB11A TFF3 TP53 CCND1 CDKN2A GAST
5 neoplasm MP:0002006 9.23 CCND1 CDKN2A CDX2 GAST MCM2 MUC2

Drugs & Therapeutics for Barrett Esophagus

FDA approved drugs:

(show top 50) (show all 194)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abstral 18 FENTANYL (citrate) ProStrakan January 2011
2
Actiq 18 FENTANYL (citrate) Anesta Corporation November 1998
3
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
4
Afinitor 18 49 EVEROLIMUS Novartis March 2009
5
Akynzeo 18 49 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn October 2014
6
Aloxi 18 49 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare August 2003
7
Anexsia 18 ACETAMINOPHEN; HYDROCODONE BITARTRATE Mallinckrodt Group August 1996
8
Aredia 18 49 PAMIDRONATE DISODIUM Chiron August 1996
9
Arimidex 18 49 ANASTROZOLE AstraZeneca January 1996
10
Aromasin Tablets 18 49 EXEMESTANE Pharmacia & Upjohn October 21. 1999
11
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
12
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
13
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
14
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
15
Campostar 18 49 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn June 1996
16
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
17
Clolar 18 49 CLOFARABINE Genzyme December, 2004
18
Cometriq 18 49 CABOZANTINIB S-MALATE Exelixis November 2012
19
Degarelix 18 49 degarelix Ferring Pharmaceuticals December of 2008
20
Elitek 18 49 RASBURICASE sanofi-aventis October 2009
21
Ellence 18 49 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn September 1999
22
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
23
Erwinaze 18 49 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
24
Ethyol 18 AMIFOSTINE Alza December 8, 1995
25
Eulexin 18 FLUTAMIDE Schering-Plough June 1996
26
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
27
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
28
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
29
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
30
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
31
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
32
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
33
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
34
Hycamtin 18 49 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
35
Ibrance 18 49 PALBOCICLIB Pfizer February 2015
36
Iclusig 18 49 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
37
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
38
Inlyta 18 49 AXITINIB Pfizer January 2012
39
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
40
Iressa 18 49 GEFITINIB AstraZeneca May 2003
41
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
42
Ixempra 18 49 IXABEPILONE Bristol-Myers Squibb October 2007
43
Jevtana 18 49 CABAZITAXEL sanofi aventis June 2010
44
Kadcyla 18 49 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
45
Kadian 18 MORPHINE SULFATE Purepac Pharmaceutical July 1996
46
Keytruda 18 49 PEMBROLIZUMAB Merck September 2014
47
Kyprolis 18 49 CARFILZOMIB Onyx Pharmaceuticals July 2012
48
Lazanda 18 FENTANYL CITRATE Archimedes June 2011
49
Lenvima 18 49 LENVATINIB MESYLATE Eisai February 2015
50
Leukine 18 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996

Drugs for Barrett Esophagus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
3
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
4
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 73590-58-6 4594
5
Dexlansoprazole Approved, Investigational Phase 4,Phase 2 138530-94-6, 103577-45-3 9578005
6
Lansoprazole Approved, Investigational Phase 4,Phase 2 103577-45-3 3883
7
Dinoprostone Approved Phase 4 363-24-6 5280360
8
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
9
Phenylephrine Approved Phase 4 59-42-7 6041
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
Pantoprazole Approved Phase 4,Phase 3 102625-70-7 4679
14 Liver Extracts Phase 4
15 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
16 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
17 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
18 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Analgesics Phase 4,Phase 3,Phase 2
20 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
23 Antipyretics Phase 4,Phase 3,Phase 2
24 Antirheumatic Agents Phase 4,Phase 3,Phase 2
25 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2
26 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
28 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
29 Anesthetics Phase 4,Not Applicable,Early Phase 1
30 Hormones Phase 4,Phase 2,Not Applicable,Early Phase 1
31 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Cyclooxygenase 2 Inhibitors Phase 4,Phase 2
33 Neuroprotective Agents Phase 4,Phase 1
34 Hormone Antagonists Phase 4,Phase 2,Early Phase 1
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Early Phase 1
36 Antiemetics Phase 4
37 Antineoplastic Agents, Hormonal Phase 4,Early Phase 1
38 Autonomic Agents Phase 4
39 glucocorticoids Phase 4
40 Methylprednisolone acetate Phase 4
41 Methylprednisolone Hemisuccinate Phase 4
42 Prednisolone acetate Phase 4
43 Prednisolone hemisuccinate Phase 4
44 Prednisolone phosphate Phase 4
45 Omega 3 Fatty Acid Nutraceutical Phase 4
46
Trioxsalen Approved Phase 2, Phase 3,Phase 3 3902-71-4 5585
47
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
48
Ranitidine Approved Phase 3 66357-59-3, 66357-35-5 3001055
49
Melatonin Approved, Nutraceutical, Vet_approved Phase 3 73-31-4 896
50
acetic acid Approved, Nutraceutical Phase 2, Phase 3,Not Applicable 64-19-7 176

Interventional clinical trials:

(show top 50) (show all 255)
# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients Completed NCT00352261 Phase 4 Esomeprazole;Lansoprazole
3 Barrett's Esophagus - 315 - 3 Way Cross-Over Completed NCT00637559 Phase 4 Esomeprazole Magnesium
4 Barrett's Esophagus - 315 - 3 Way Cross Over Completed NCT00637988 Phase 4 Esomeprazole;Aspirin;Rofecoxib
5 Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation? Completed NCT01093755 Phase 4 dexlansoprazole;Omeprazole
6 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Completed NCT00754468 Phase 4
7 Radiofrequency Ablation for the Treatment of Gastric Dysplasia Completed NCT01523912 Phase 4
8 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
9 Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids Recruiting NCT01733147 Phase 4 Omega-3 free fatty acids;Placebo
10 Radiofrequency in the Treatment of Barrett's Oesophagus Recruiting NCT02558504 Phase 4
11 Cryo Balloon for Residual Barrett's Esophagus Enrolling by invitation NCT02230410 Phase 4
12 Barretts oEsophageal Resection With Steroid Therapy Trial Not yet recruiting NCT02004782 Phase 4 Prednisolone;Placebo Oral Tablet
13 Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease Not yet recruiting NCT03467438 Phase 4 Zinc-l-carnosine
14 Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus Terminated NCT00526786 Phase 4
15 A Trial Comparing Yield of Confocal Endomicroscopy Guided Biopsies Terminated NCT01030263 Phase 4
16 Reduction in Symptomatic Esophageal Stricture Formation Terminated NCT02039115 Phase 4 prednisone;placebo
17 The Clinical Significance of Acid Rebound in Functional Dyspepsia Terminated NCT01373970 Phase 4 Placebo;Pantoprazole + Placebo
18 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
19 Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study Unknown status NCT01566474 Phase 3 Omeprazole;Melatonin
20 Biomarkers in Phototherapy of Barrett's Esophagus Completed NCT00587600 Phase 2, Phase 3
21 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
22 "Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance Recruiting NCT02614703 Phase 2, Phase 3 Chromoendoscopy using Acetic Acid 2.5%
23 An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric Recruiting NCT03285906 Phase 2, Phase 3 Apatinib
24 Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor Terminated NCT00161200 Phase 3 Ranitidine & Pantoprazole
25 Safety of Photodynamic Therapy (PDT) in the Ablation of High-grade Dysplasia (HGD) in Barrett's Esophagus (BE) Withdrawn NCT01209013 Phase 3
26 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
27 Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus Completed NCT01447927 Phase 2 metformin hydrochloride
28 Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus Completed NCT00474903 Phase 2 acetylsalicylic acid;esomeprazole magnesium
29 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
30 Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium Completed NCT02249975 Phase 1, Phase 2
31 Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia Completed NCT01097304 Phase 2 Ursodiol
32 Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus Completed NCT00005878 Phase 2 celecoxib
33 Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus Completed NCT00003076 Phase 2 eflornithine
34 Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer Completed NCT00411151 Phase 2 Sunitinib-Malate
35 Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer Completed NCT00281736 Phase 2 HPPH
36 Photodynamic Therapy in Treating Patients With Early Esophageal Cancer Completed NCT00002935 Phase 2 porfimer sodium
37 Radiofrequency Ablation for Gastric Metaplasia and Dysplasia Completed NCT01614418 Phase 1, Phase 2
38 The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus Recruiting NCT03193216 Phase 2 Alginates
39 Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma Recruiting NCT02018367 Phase 2 Proflavine, high resolution imaging
40 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Recruiting NCT03302858 Phase 2
41 Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus Active, not recruiting NCT01298999 Phase 2 YF476;Placebo
42 Radiofrequency Ablation for Barrett Oesophagus With Low Grade Dysplasia Active, not recruiting NCT01360541 Phase 2
43 Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation Active, not recruiting NCT02521285 Phase 2 Aspirin
44 YF476 in Barrett's Esophagus Enrolling by invitation NCT02597712 Phase 2 YF476;YF476 placebo
45 Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation Terminated NCT02162758 Phase 2 Dexlansoprazole;Dexlansoprazole Placebo
46 Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer Terminated NCT00321958 Phase 2
47 Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light Withdrawn NCT01256203 Phase 2 Solar Protection Formula SPF® 60
48 The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus Unknown status NCT01905202 Phase 1 Secretrol
49 Erlotinib in Treating Patients With Barrett Esophagus Unknown status NCT00566800 Phase 1 erlotinib hydrochloride
50 Effect of Zinc on Barrett's Metaplasia Unknown status NCT01984580 Phase 1 zinc gluconate

Search NIH Clinical Center for Barrett Esophagus

Cochrane evidence based reviews: barrett esophagus

Genetic Tests for Barrett Esophagus

Genetic tests related to Barrett Esophagus:

# Genetic test Affiliating Genes
1 Barrett Esophagus 29 ASCC1 CTHRC1 MSR1

Anatomical Context for Barrett Esophagus

MalaCards organs/tissues related to Barrett Esophagus:

41
Lung, Breast, Endothelial, Testes, Skin, Prostate, Heart

Publications for Barrett Esophagus

Articles related to Barrett Esophagus:

(show top 50) (show all 117)
# Title Authors Year
1
Gastroesophageal Reflux Frequency, Severity, Age of Onset, Family History and Acid Suppressive Therapy Predict Barrett Esophagus in a Large Population. ( 29356784 )
2018
2
Microsatellite instability in metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus: a retrospective study. ( 29972732 )
2018
3
Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. ( 29608452 )
2018
4
Carcinoma in situ within an area of Barrett esophagus in a dog with megaesophagus. ( 29952726 )
2018
5
Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma - where do we stand? ( 29972731 )
2018
6
Comparative Assessment of Patient Preferences and Tolerability in Barrett Esophagus Screening: Results From a Randomized Trial. ( 29369237 )
2018
7
Definition of Barrett Esophagus in the United States: Support for Retention of a Requirement for Goblet Cells. ( 29016405 )
2018
8
Evaluation of p53 protein expression in Barrett esophagus. ( 29676351 )
2018
9
Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus. ( 29959150 )
2018
10
Evaluation of Dysplasia in Barrett Esophagus. ( 29942221 )
2018
11
Efficacy, Durability, and Safety of Complete Endoscopic Mucosal Resection of Barrett Esophagus: A Systematic Review and Meta-Analysis. ( 28134635 )
2018
12
Treating Barrett esophagus with radiofrequency ablation. ( 29280837 )
2018
13
Whole Genome Methylation Analysis of Nondysplastic Barrett Esophagus that Progresses to Invasive Cancer. ( 29384778 )
2018
14
Substantial Interobserver Agreement in the Diagnosis of Dysplasia in Barrett Esophagus Upon Review of a Patient's Entire Set of Biopsies. ( 29135518 )
2018
15
Optical Coherence Tomography for Barrett Esophagus. ( 29942226 )
2018
16
Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma. ( 28501084 )
2017
17
Barrett Esophagus ( 28613697 )
2017
18
Hepatocyte Antigen Expression in Barrett Esophagus and Associated Neoplasia. ( 28187035 )
2017
19
Acetic Acid Chromoendoscopy in the Setting of Neoplastic Barrett Esophagus. ( 28867985 )
2017
20
The Use of Ancillary Stains in the Diagnosis of Barrett Esophagus and Barrett Esophagus-associated Dysplasia: Recommendations From the Rodger C. Haggitt Gastrointestinal Pathology Society. ( 28248814 )
2017
21
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. ( 28184414 )
2017
22
Current Endoscopic Approaches for the Treatment of Barrett Esophagus. ( 27941583 )
2017
23
Current Management of Low-Grade Dysplasia in Barrett Esophagus. ( 28546793 )
2017
24
Hybrid Argon Plasma Coagulation in Patients With Barrett Esophagus. ( 29230137 )
2017
25
Human papillomavirus does not play a role in the Barrett esophagus: a French cohort. ( 28881904 )
2017
26
IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus. ( 26766126 )
2017
27
Early Barrett esophagus-related neoplasia in segments 1a88cm or longer is always associated with intestinal metaplasia. ( 28548120 )
2017
28
Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study. ( 28422774 )
2017
29
Metabolic syndrome is associated with increased risk of Barrett esophagus: A meta-analysis. ( 27495039 )
2016
30
Volumetric Laser Endomicroscopy in Patients With Barrett Esophagus. ( 28035200 )
2016
31
Columnar Metaplasia in the Esophageal Remnant After Esophagectomy: A Common Occurrence and a Valuable Insight Into the Development of Barrett Esophagus. ( 26756755 )
2016
32
Prevalence of Barrett Esophagus in Adolescents and Young Adults With Esophageal Atresia. ( 27163954 )
2016
33
The Prevalence of Barrett Esophagus Diagnosed in the Second Endoscopy: A Retrospective, Observational Study at a Tertiary Center. ( 27057907 )
2016
34
Molecular pathogenesis of Barrett esophagus: current evidence. ( 26021192 )
2015
35
Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. ( 24668102 )
2014
36
Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. ( 23842216 )
2014
37
Barrett esophagus: history, definition and etiopathogeny. ( 25870690 )
2014
38
RING finger proteins are involved in the progression of barrett esophagus to esophageal adenocarcinoma: a preliminary study. ( 25228972 )
2014
39
Metastatic melanoma in an esophagus demonstrating Barrett esophagus with high grade dysplasia. ( 24220097 )
2013
40
Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. ( 23108119 )
2013
41
Current readings: Endoesophageal management of early esophageal cancer and dysplastic barrett esophagus: a review of recent and influential studies. ( 24216531 )
2013
42
Barrett esophagus and risk of esophageal cancer: a clinical review. ( 23942681 )
2013
43
Barrett esophagus and esophagojejunal anastomotic stenosis as complications of esophagogastric disconnection in children with esophageal atresia. ( 23535759 )
2013
44
Advanced esophageal cancer in patients who underwent radiofrequency ablation for barrett esophagus with high-grade dysplasia. ( 23571789 )
2013
45
Hepatocyte paraffin 1 antigen as a biomarker for early diagnosis of Barrett esophagus. ( 22180484 )
2012
46
Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus. ( 22603795 )
2012
47
Inverse association of esophageal eosinophilia and Barrett esophagus. ( 22751337 )
2012
48
Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. ( 22344232 )
2012
49
Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. ( 22355271 )
2012
50
Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to carcinogenesis in Barrett Esophagus? ( 22261707 )
2012

Variations for Barrett Esophagus

ClinVar genetic disease variations for Barrett Esophagus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MSR1 NM_138715.2(MSR1): c.760C> G (p.Leu254Val) single nucleotide variant Pathogenic rs387906645 GRCh37 Chromosome 8, 16021631: 16021631
2 MSR1 NM_138715.2(MSR1): c.760C> G (p.Leu254Val) single nucleotide variant Pathogenic rs387906645 GRCh38 Chromosome 8, 16164122: 16164122
3 CTHRC1 NM_138455.3(CTHRC1): c.131A> C (p.Gln44Pro) single nucleotide variant Pathogenic rs387907029 GRCh37 Chromosome 8, 104384015: 104384015
4 CTHRC1 NM_138455.3(CTHRC1): c.131A> C (p.Gln44Pro) single nucleotide variant Pathogenic rs387907029 GRCh38 Chromosome 8, 103371787: 103371787
5 ASCC1 NM_001198799.2(ASCC1): c.953A> G (p.Asn318Ser) single nucleotide variant Pathogenic rs146370051 GRCh37 Chromosome 10, 73892817: 73892817
6 ASCC1 NM_001198799.2(ASCC1): c.953A> G (p.Asn318Ser) single nucleotide variant Pathogenic rs146370051 GRCh38 Chromosome 10, 72133059: 72133059

Copy number variations for Barrett Esophagus from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18052 1 143700001 144900000 Amplification BCL9 Esophageal adenocarcinoma
2 19685 1 151000001 155000000 Amplification SKI Esophageal adenocarcinoma
3 21958 1 163432534 163614111 Gain and loss LMX1A Barrett''s syndrome
4 25140 1 184717073 186846060 Gain and loss PLA2G4A Barrett''s syndrome
5 25141 1 184717073 186846060 Gain and loss PTGS2 Barrett''s syndrome
6 29301 1 2300000 5400000 Copy number Esophageal adenocarcinoma
7 33578 1 46425202 46624292 Loss RAD54L Barrett''s syndrome
8 37058 1 84900000 107200000 Loss F3 Esophageal adenocarcinoma
9 39044 10 108165938 109275992 Loss SORCS1 Barrett''s syndrome
10 39081 10 109092539 133471230 Loss BUB3 Barrett''s syndrome
11 39082 10 109092539 133471230 Loss C10orf119 Barrett''s syndrome
12 39083 10 109092539 133471230 Loss NANOS1 Barrett''s syndrome
13 39407 10 114856262 115024106 Loss TCF7L2 Barrett''s syndrome
14 47055 10 89500000 92900000 Copy number Esophageal adenocarcinoma
15 49101 11 102900000 110400000 Copy number Esophageal adenocarcinoma
16 50933 11 120168346 133686875 Loss CHEK1 Barrett''s syndrome
17 50934 11 120168346 133686875 Loss ETS1 Barrett''s syndrome
18 50935 11 120168346 133686875 Loss TIRAP Barrett''s syndrome
19 52231 11 149520 6642613 Loss MUC6 Barrett''s syndrome
20 52232 11 149520 6642613 Loss RHOG Barrett''s syndrome
21 53078 11 2400000 5900000 Copy number CDKN1C Esophageal adenocarcinoma
22 54793 11 474042 626401 Loss HRAS Barrett''s syndrome
23 54794 11 474042 626401 Loss MUPCDH Barrett''s syndrome
24 54795 11 474042 626401 Loss RASSF7 Barrett''s syndrome
25 54796 11 474042 626401 Loss RNH1 Barrett''s syndrome
26 54797 11 474042 626401 Loss SCT Barrett''s syndrome
27 57455 11 63400000 77100000 Gain CCND1 Esophageal adenocarcinoma
28 57457 11 63400000 77100000 Gain EMS1 Esophageal adenocarcinoma
29 57458 11 63400000 77100000 Gain FGF3 Esophageal adenocarcinoma
30 60370 11 8555485 8795697 Loss ST5 Barrett''s syndrome
31 60371 11 8555485 8795697 Loss STK33 Barrett''s syndrome
32 64928 12 133416937 133464204 Copy number CHFR Esophageal adenocarcinoma
33 76216 13 28900000 32200000 Gain BRCA2 Esophageal adenocarcinoma
34 80630 13 95000000 115169878 Gain ABCC4 Esophageal adenocarcinoma
35 80631 13 95000000 115169878 Gain ING1 Esophageal adenocarcinoma
36 83864 14 22278370 23705612 Gain and loss MMP14 Barrett''s syndrome
37 83865 14 22278370 23705612 Gain and loss PCK2 Barrett''s syndrome
38 86372 14 58681498 106175506 Gain and loss FOXN3 Barrett''s syndrome
39 86373 14 58681498 106175506 Gain and loss MAX Barrett''s syndrome
40 86374 14 58681498 106175506 Gain and loss MLH3 Barrett''s syndrome
41 92864 15 44800000 63700000 Loss B2M Esophageal adenocarcinoma
42 95624 15 78300000 102531392 Loss IGF1R Esophageal adenocarcinoma
43 105274 16 77215302 77345302 Loss WWOX Barrett''s syndrome
44 105374 16 7900000 10500000 Copy number Esophageal adenocarcinoma
45 106764 17 1 20774742 Copy number MYBBP1A Esophageal adenocarcinoma
46 106765 17 1 20774742 Copy number TP53 Esophageal adenocarcinoma
47 108120 17 18863807 19044654 Loss GRAP Barrett''s syndrome
48 109777 17 2912016 3092354 Gain and loss Barrett''s syndrome
49 109778 17 2912016 3092354 Gain and loss Esophageal adenocarcinoma
50 110805 17 34303536 34308523 Gain SCYA3 Esophageal adenocarcinoma

Expression for Barrett Esophagus

Search GEO for disease gene expression data for Barrett Esophagus.

Pathways for Barrett Esophagus

GO Terms for Barrett Esophagus

Cellular components related to Barrett Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC2 MUC5AC MUC6

Biological processes related to Barrett Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G1/S transition of mitotic cell cycle GO:0000082 9.54 CCND1 CDKN2A MCM2
2 response to estradiol GO:0032355 9.5 CCND1 GSTP1 PTGS2
3 replicative senescence GO:0090399 9.26 CDKN2A TP53
4 maintenance of gastrointestinal epithelium GO:0030277 9.16 MUC2 MUC6
5 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
6 O-glycan processing GO:0016266 8.8 MUC2 MUC5AC MUC6

Molecular functions related to Barrett Esophagus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 ASCC1 CCND1 CDKN2A GAST GDF7 GSTP1

Sources for Barrett Esophagus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....